MDMA-Assisted Therapy for PTSD: 11 Powerful Takeaways From Phase 3 Results, FDA’s Rejection, and New Ketamine+WET Findings

Blog post dMDMA-assisted therapy for PTSD: We compare Phase 3 MDMA-assisted therapy results versus control, unpack why the FDA rejected Lykos Therapeutics’ application over “functional unblinding,” and spotlight a 2025 open-label trial pairing six ketamine infusions with Written Exposure Therapy (WET), with clear actions for clinicians and policy-watchers.

MENTAL HEALTH INSIGHTSHEALTH & WELLNESS